{
    "clinical_study": {
        "@rank": "116181", 
        "arm_group": {
            "arm_group_label": "single arm, Liposuction, BonoFill Transplantation", 
            "arm_group_type": "Experimental", 
            "description": "Liposuction - will be performed on Visit 2 for all eligible subjects\nBonoFill Transplantation  - will be performed on Visit 6 for all eligible subjects"
        }, 
        "brief_summary": {
            "textblock": "Phase I/II open label first in human single center  clinical study, is to evaluate the\n      safety and the efficacy of BonoFill as bone filler containing the patient own (autologous)\n      adipose tissue derived cells (HATDCs) in reconstructing the Bone Void in the maxillofacial\n      area approximately 6 month follow up after implantation in the following two clinical\n      indications:\n\n        1. Bone augmentation (e.g. sinus augmentation)\n\n        2. Bone grafting after  removal of cysts from jaws"
        }, 
        "brief_title": "Filling Bone Defects/Voids With Autologous BonoFill For Maxillofacial Bone Regeneration", 
        "condition": "Bone Void in the Maxillofacial Area", 
        "detailed_description": {
            "textblock": "Primary endpoint: The implantation of BonoFill to the maxillary or mandible defect/void is\n      safe under the following conditions: No chronic bone infection (Osteomyelitis); no\n      significant changes in complete blood count (CBC) and in general health.\n\n      Secondary endpoint: The implantation of BonoFill to the maxillary or mandible void is\n      efficient under the following conditions: Following BonoFill implantation, the bone\n      regeneration in the operated site was significantly accelerated. Also, the bone\n      defects/voids were filled with a significant amount of bone tissue."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        The inclusion criteria defining the eligible subjects are divided to two groups according\n        clinical indications:\n\n        Sinus augmentation\n\n          -  Subjects in general good health in the opinion of the investigator as determined by\n             medical history, vital signs physical examination and safety lab tests\n\n          -  Subjects that have a rehabilitation dentist and rehabilitation program\n\n          -  Up to dated panoramic X-Ray.\n\n          -  Subjects who provided written informed consent to participate in the study, able to\n             understand study procedure and agree for follow up procedures\n\n          -  Healthy conditions of Maxillary Sinuses and Oral Mucosa.\n\n          -  Sub-antral bone at least 4 mm as measured on CBCT/CT.\n\n          -  Have a good oral hygiene condition as per investigator discretion.\n\n        Bone grafting after  removal of cysts from jaws\n\n          -  Healthy subject.\n\n          -  Subjects that have a rehabilitation dental treatment.\n\n          -  Limited to cysts diagnosed as: radicular cysts, residual cysts, congenital cysts,\n             developmental and acquired cysts.\n\n          -  Subjects referred to oral & maxillofacial Dpt for removal of cysts after diagnosis of\n             the cyst type.\n\n          -  Healthy bone determined by X-ray.\n\n          -  Have a good oral hygiene condition.\n\n          -  Subject that does not participate in other clinical study.\n\n          -  Subject able to read and understand and sign the informed consent\n\n        Exclusion Criteria:\n\n          -  Subjects with recorded medical history diseases as: diabetes mellitus, heart\n             diseases, renal failure, osteoporosis.\n\n          -  Subject treated with systemic steroid treatment\n\n          -  Subjects with known autoimmune diseases, such as: Addison's disease Celiac disease -\n             sprue (gluten-sensitive enteropathy), Dermatomyositis Graves disease, Hashimoto's\n             thyroiditis, Multiple sclerosis, Myasthenia gravis Pernicious anemia, Reactive\n             arthritis, Rheumatoid arthritis, Sjogren syndrome Systemic lupus erythematosus, Type\n             I diabetes.\n\n          -  Subjects that have Vitiligo and/or known scar healing problems (keloid formation).\n\n          -  Subjects treated with anticoagulation medication (such as Coumadin, Plavix and other\n             similar medications)\n\n          -  Subjects treated with Oral Bisphosphonate drugs (such as Fosalan and other similar\n             medications)\n\n          -  Subjects with a history of Chemotherapy or Radiotherapy treatment\n\n          -  In case of sinus augmentation - Unhealthy conditions of Maxillary Sinuses.\n\n          -  Subjects with current active infection or illness\n\n          -  Subjects participating in another clinical trial 30 days prior to and during the\n             study period\n\n          -  Pregnant or lactating woman. Pregnancy will be verified by urine test during\n             screening\n\n          -  Known history of any significant medical disorder, which in the investigator's\n             judgment contraindicates the subject's participation\n\n          -  Subjects with any known allergy for anesthesia\n\n          -  Positive serology for either HIV, hepatitis B or hepatitis C\n\n          -  Abnormal clinically significant as per investigator's judgment laboratory test and\n             exams findings"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02153268", 
            "org_study_id": "CP-BNS-02"
        }, 
        "intervention": {
            "arm_group_label": "single arm, Liposuction, BonoFill Transplantation", 
            "description": "Liposuction - will be performed on Visit 2, BonoFill will be based on subject's autologous Human Adipose Tissue Derived Cells (HATDCs).\nBonoFill Transplantation will be performed on Visit 6. BonoFill will be administrated to the subject in a single session at one tested cell dose.", 
            "intervention_name": "Single Arm - Liposuction procedure and BonoFill transplantation will be done for all subjects on study", 
            "intervention_type": "Procedure", 
            "other_name": [
                "BonoFill is an Biological, cell therapy Product that complies with the definition of Somatic Cell Therapies", 
                "BonoFill is an autologous Human Adipose Tissue Derived Cells (HATDCs) based product, combined with OraGraft\u00ae mineral particles."
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Safety", 
            "efficacy", 
            "BonoFill", 
            "bone filler", 
            "autologous adipose tissue derived cells (HATDCs)", 
            "Bone augmentation", 
            "sinus augmentation", 
            "Bone grafting after  removal of cysts from jaws"
        ], 
        "lastchanged_date": "June 2, 2014", 
        "location": {
            "contact": {
                "email": "ephraimdr@gmail.com", 
                "last_name": "Ephraim Zur, Dr. DMD", 
                "phone": "+97297456666"
            }, 
            "contact_backup": {
                "last_name": "Limor Alkalay", 
                "phone": "+97297456666"
            }, 
            "facility": {
                "address": {
                    "city": "Kfar Saba", 
                    "country": "Israel"
                }, 
                "name": "Dr. Ephraim Zur Dental Clinic"
            }, 
            "investigator": {
                "last_name": "Yaniv Stolero, DMD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I/II Open Label FIH Single Center Clinical Study Aimed to Evaluate the Safety and the Efficacy of BonoFill in Reconstructing the Bone.", 
        "overall_contact": {
            "email": "Orabu@bonus-bio.com", 
            "last_name": "Ora Burger, Dr. PhD", 
            "phone": "+972 (73) 206 7102"
        }, 
        "overall_official": {
            "affiliation": "MY", 
            "last_name": "Yaniv Stolero, Dr", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The implantation of BonoFill to the maxillary or mandible defect/void is safe under the following conditions: No chronic bone infection (Osteomyelitis); no significant changes in complete blood count (CBC) and in general health.", 
            "measure": "BonoFill is safe", 
            "safety_issue": "Yes", 
            "time_frame": "approximately 6 month follow up after implantation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02153268"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The implantation of BonoFill to the maxillary or mandible void is efficient under the following conditions: Following BonoFill implantation, the bone regeneration in the operated site was significantly accelerated. Also, the bone defects/voids were filled with a significant amount of bone tissue.", 
            "measure": "BonoFill is efficient", 
            "safety_issue": "No", 
            "time_frame": "approximately 6 month follow up after implantation"
        }, 
        "source": "BonusBio Group Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "BonusBio Group Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}